First-trimester fetal heart rate in mothers with opioid addiction

Addiction

Volumn 105, Issue 7, 2010, Pages 1265-1268

  Schmid, Maximilian ^a   Kuessel, Lorenz ^a   Klein, Katharina ^a   Metz, Verena ^a   Fischer, Gabriele ^a   Krampl Bettelheim, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fetal heart rate; First trimester; Opioid addiction; Pregnancy; Ultrasound

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; DRUG EFFECT; FEMALE; FETUS ECHOGRAPHY; FETUS HEART RATE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MOTHER; NUCHAL TRANSLUCENCY MEASUREMENT; OPIATE ADDICTION; PREGNANCY; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY;

ADULT; ANALGESICS, OPIOID; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HEART RATE, FETAL; HUMANS; MOTHERS; NUCHAL TRANSLUCENCY MEASUREMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, PRENATAL;

EID: 77953297556     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.02982.x     Document Type: Article

References (27)

1. Azadi A., Dildy G. A. III. Universal screening for substance abuse at the time of parturition. Am J Obstet Gynecol 2008 198 : e30 e32.
2. Gyarmathy V. A., Giraudon I., Hedrich D., Montanari L., Guarita B., Wiessing L. Drug use and pregnancy - challenges for public health. Eur Surveill 2009 14 : 33 6.
3. Minozzi S., Amato L., Vecchi S., Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008 2 : CD006318.
4. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006 101 : 275 281.
5. Kandall S. R., Albin S., Gartner L. M., Lee K. S., Eidelman A., Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977 1 : 159 169.
6. Harper R. G., Solish G., Feingold E., Gersten-Woolf N. B., Sokal M. M. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977 129 : 417 424.
7. Chasnoff I. J., Burns W. J., Schnoll S. H. Perinatal addiction: the effects of maternal narcotic and nonnarcotic substance abuse on the fetus and neonate. NIDA Res Monogr 1984 49 : 220 226.
8. Leiva M. C., Tolosa J. E., Binotto C. N., Weiner S., Huppert L., Denis A. L. et al. Fetal cardiac development and hemodynamics in the first trimester. Ultrasound Obstet Gynecol 1999 14 : 169 174.
9. Liao A. W., Snijders R., Geerts L., Spencer K., Nicolaides K. H. F. et al. Heart rate in chromosomally abnormal fetuses. Ultrasound Obstet Gynecol 2000 16 : 610 613.
10. Yagel S., Cohen S. M., Messing B. First and early second trimester fetal heart screening. Curr Opin Obstet Gynecol 2007 19 : 183 190.
11. Sciarrone A., Masturzo B., Botta G., Bastonero S., Campogrande M., Viora E. First-trimester fetal heart block and increased nuchal translucency: an indication for early fetal echocardiography. Prenat Diagn 2005 25 : 1129 1132.
12. Baschat A. A., Gembruch U., Knopfle G., Hansmann M. First-trimester fetal heart block: a marker for cardiac anomaly. Ultrasound Obstet Gynecol 1999 14 : 311 314.
13. Achiron R., Tadmor O., Mashiach S. Heart rate as a predictor of first-trimester spontaneous abortion after ultrasound-proven viability. Obstet Gynecol 1991 78 : 330 334.
14. Kagan K. O., Wright D., Valencia C., Maiz N., Nicolaides K. H. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008 23 : 1968 1975.
15. Navaneethakrishnan R., Tutty S., Sinha C., Lindow S. W. The effect of maternal methadone use on the fetal heart pattern: a computerised CTG analysis. Br J Obstet Gynaecol 2006 113 : 948 950.
16. Jansson L. M., Dipietro J., Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005 193 : 611 617.
17. Jansson L. M., Dipietro J. A., Velez M., Elko A., Knauer H., Kivlighan K. T. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009 22 : 29 35.
18. Anyaegbunam A., Tran T., Jadali D., Randolph G., Mikhail M. S. Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Gynecol Obstet Invest 1997 43 : 25 8.
19. Levine A. B., Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995 15 : 229 231.
20. Ramirez-Cacho W. A., Flores S., Schrader R. M., McKay J., Rayburn W. F. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Invest 2006 13 : 108 111.
21. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008 103 : 1429 1440.
22. Habek D. Effects of smoking and fetal hypokinesia in early pregnancy. Arch Med Res 2007 38 : 864 867.
23. Nicolaides K. H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992 304 : 867 869.
24. Snijders R. J., Noble P., Sebire N., Souka A., Nicolaides K. H. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998 352 : 343 346.
25. Ray S. B., Wadhwa S. Mu opioid receptors in developing human spinal cord. J Anat 1999 195 : 11 8.
26. Scott G. J., Holding S., Purcell A., Tutty S., Lindow S. W. The influence of maternal opiate use in pregnancy on second trimester biochemical markers for Down syndrome. Prenat Diagn 2009 29 : 863 865.
27. Winklbaur B., Baewert A., Jagsch R., Rohrmeister K., Metz V., Aeschbach J. C. et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009 15 : 150 156.